Apyx Medical Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +6.73%.
Did APYX Beat Earnings? Q1 2025 Results
Apyx Medical posted a narrower-than-expected loss in Q1 2025, delivering an earnings beat even as revenue slipped year-over-year, with aggressive cost discipline emerging as the defining story of the quarter. The medical device maker reported revenue of $9.43 million, down 8% from a year ago but edging past the $9.33 million consensus estimate by 1.04%, while its loss per share of $0.10 beat the $0.12 estimate by 13.04%. The headline decline was almost entirely driven by a 45% collapse in OEM segment revenue to $1.54 million, which obscured a 6% gain in the core Advanced Energy segment to $7.89 million, fueled by strong domestic generator and handpiece sales. The more compelling development was a $3.80 million reduction in total operating expenses, which helped cut the net loss nearly in half to $4.15 million. Management reaffirmed full-year 2025 revenue guidance of $47.60 million to $49.00 million, and the company has since received FDA clearance for its AYON Body Contouring System, setting up a commercial launch in the second half of 2025 as a potential growth catalyst.
- Strong domestic generator unit sales driving Advanced Energy growth
- U.S. single-use handpiece revenue grew 14% year-over-year
- Cost-cutting measures from Q4 2024 reduced operating expenses by $3.8 million
- Improved gross margin to 60% from 58% due to favorable product and geographic mix
- OEM revenue declined 45% due to decreased sales volume to existing customers
“We have made steady progress executing against our commercial strategy to position Apyx as the leader in surgical aesthetics. We believe Renuvion, which is the only FDA-cleared device for use after liposuction, is positioned to be the standard-of-care for the rapidly growing patient population on GLP-1 drugs that choose to address their loose skin post-weight loss. This is an exciting new opportunity within the industry that we believe offers our company tremendous opportunities for future growth.”
Apyx Medical CEO, on the earnings call
Forward Guidance & Outlook
The company reaffirmed full-year 2025 financial guidance: total revenue of $47.6 million to $49.0 million (compared to $48.1 million in 2024), with Advanced Energy revenue of $39.6 million to $41.0 million and OEM revenue of approximately $8.0 million. Total operating expenses are expected to be less than $40.0 million. The company plans to launch the AYON Body Contouring System in the second half of 2025, pending FDA clearance, after submitting a 510(k) premarket notification in Q1 2025. The company is actively monitoring trade policy and tariff developments, noting that tariffs may make its products less cost competitive and reduce gross margins, though it intends to utilize its U.S. and Bulgaria manufacturing locations to minimize impact.
APYX YoY Financials
APYX Revenue by Segment
APYX Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.